Antitumor activity of Gilteritinib, an inhibitor of AXL, in human solid tumor

Abstract excerpt

<title>Abstract</title> <p>AXL, a receptor tyrosine kinase, has recently emerged as a potential therapeutic target against various cancer types. Gilteritinib, a FDA-approved small-molecule inhibitor, is used for the treatment of patients with FLT3-mutated acute myeloid leukemia. However, the antitumor activity of Gilteritinib in solid tumors remains poorly elucidated. Here, The antitumor activity of Gilteritinib...

Topics

Open a Topic to create a Post that cites this publication.

• Aniline Compounds
• fms-Like Tyrosine Kinase 3
• Japan
• Leukemia, Myeloid, Acute
• Mutation
• Phagocytosis and Immune Regulation
• Protein Kinase Inhibitors
• Pyrazines

Identifiers and source

Literature Corpus work

bb8575d3-5167-5e66-8b1c-5fe0fa2e5549

DOI

10.21203/rs.3.rs-5413278/v1